Display options
Cite
Kim JH, Zang DY, Chung IJ, et al. A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal Cancer. J Cancer. 2015;6(10):1041-8doi: 10.7150/jca.12819.
Kim, J. H., Zang, D. Y., Chung, I. J., Cho, S. H., Park, K. U., Oh, H. S., Lee, K. H., Lee, B. H., Kim, M. J., Park, C. K., Han, B., Kim, H. S., Choi, D. R., Song, H. H., & Jung, J. Y. (2015). A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal Cancer. Journal of Cancer, 6(10), 1041-8. https://doi.org/10.7150/jca.12819
Kim, Jung Han, et al. "A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal Cancer." Journal of Cancer vol. 6,10 (2015): 1041-8. doi: https://doi.org/10.7150/jca.12819
Kim JH, Zang DY, Chung IJ, Cho SH, Park KU, Oh HS, Lee KH, Lee BH, Kim MJ, Park CK, Han B, Kim HS, Choi DR, Song HH, Jung JY. A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal Cancer. J Cancer. 2015 Aug 29;6(10):1041-8. doi: 10.7150/jca.12819. eCollection 2015. PMID: 26366218; PMCID: PMC4565854.
Copy Download .nbib Format: NLM
Share it on

J Cancer. 2015 Aug 29;6(10):1041-8. doi: 10.7150/jca.12819. eCollection 2015.

A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal Cancer.

Journal of Cancer

Jung Han Kim, Dae Young Zang, Ik-Joo Chung, Sang-Hee Cho, Keon Uk Park, Ho-Suck Oh, Kyung Hee Lee, Bong Hwa Lee, Min-Jeong Kim, Choong Kee Park, Boram Han, Hyeong Su Kim, Dae Ro Choi, Hun Ho Song, Joo Young Jung

Affiliations

  1. 1. Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang, South Korea.
  2. 2. Department of Internal Medicine, Chonnam National University College of Medicine, Gwangju, South Korea.
  3. 3. Department of Internal Medicine, Keimyung University College of Medicine, Daegu, South Korea.
  4. 4. Department of Internal Medicine, Gangneung Asan Hospital, Gangneung, South Korea.
  5. 5. Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, South Korea.
  6. 6. Department of Surgery, Hallym University Medical Center, Hallym University College of Medicine, Anyang, South Korea.
  7. 7. Department of Radiology, Hallym University Medical Center, Hallym University College of Medicine, Anyang, South Korea.

PMID: 26366218 PMCID: PMC4565854 DOI: 10.7150/jca.12819

Abstract

BACKGROUND: Capecitabine plus oxaliplatin (XELOX) is considered one of the primary chemotherapy regimens for patients with metastatic colorectal cancer (CRC). Oxaliplatin plus S-1 (OS) has also demonstrated significant efficacy in CRC. We performed this randomized phase II study to evaluate the efficacy and toxicity of XELOX versus OS as first-line chemotherapy in patients with metastatic CRC.

METHODS: Patients were assigned randomly to receive either OS or XELOX chemotherapy. Oxaliplatin was administered intravenously to all patients at a dose of 130 mg/m(2) on day 1. Patients received either S-1 (40 mg/m(2)) or capecitabine (1,000 mg/m(2)), twice a day for 2 weeks, followed by a 1-week rest.

RESULTS: Forty-two patients were assigned to the OS arm and 44 to the XELOX arm. The overall response rate was 33.3% (95% CI, 18.8-47.2) in the OS arm and 40.9% (95% CI, 25.5-54.4) in the XELOX arm (P = 0.230). The disease control rate was significantly higher in the OS arm than the XELOX arm [92.9% (95% CI, 83.7-100) versus 77.3% (95% CI, 64.5-89.4), P = 0.044]. With a median follow up of 17.9 months, the median progression-free survival was 6.1 months in the OS arm and 7.4 months in the XELOX arm, respectively (P = 0. 599). The median survival time was 18.7 months in the OS arm and 20.1 months in the XELOX arm (P = 0.340). The most common grade 3/4 hematologic toxicity was thrombocytopenia in both arms (19.0% for OS and 28.6% for XELOX). Grade 3/4 neutropenia was observed more frequently in the XELOX arm than the OS arm (16.7% vs. 2.4%, P = 0.026).

CONCLUSION: Both OS and XELOX were effective and well tolerated in patients with metastatic CRC. Our results indicate that the combination of oxaliplatin and S-1 is a possible additional therapeutic strategy for such patients.

Keywords: Capecitabine; Colorectal neoplasm; Oxaliplatin; Randomized controlled trial; S-1

References

  1. BMC Cancer. 2014 Nov 26;14:883 - PubMed
  2. J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 - PubMed
  3. J Clin Oncol. 2001 Nov 1;19(21):4097-106 - PubMed
  4. J Clin Oncol. 2007 Sep 20;25(27):4224-30 - PubMed
  5. J Clin Oncol. 2000 Jan;18(1):136-47 - PubMed
  6. Control Clin Trials. 1989 Mar;10(1):1-10 - PubMed
  7. Br J Cancer. 2000 Jul;83(2):141-5 - PubMed
  8. Lancet Oncol. 2012 Nov;13(11):1125-32 - PubMed
  9. J Clin Oncol. 2007 Sep 20;25(27):4217-23 - PubMed
  10. J Clin Oncol. 2008 Apr 20;26(12):2006-12 - PubMed
  11. Ann Oncol. 2009 May;20(5):892-6 - PubMed
  12. Cancer. 2004 Jun 1;100(11):2355-61 - PubMed
  13. Cancer. 2004 Feb 1;100(3):531-7 - PubMed
  14. Br J Cancer. 2003 Mar 10;88(5):648-53 - PubMed
  15. J Clin Oncol. 2004 Sep 15;22(18):3766-75 - PubMed
  16. Ann Oncol. 2002 Apr;13(4):566-75 - PubMed
  17. Int J Gastrointest Cancer. 2005;35(2):103-9 - PubMed
  18. Br J Cancer. 2008 Mar 25;98(6):1034-8 - PubMed
  19. J Clin Oncol. 2003 Apr 1;21(7):1307-12 - PubMed
  20. Lancet. 2000 Mar 25;355(9209):1041-7 - PubMed
  21. J Clin Oncol. 2004 Jun 1;22(11):2084-91 - PubMed
  22. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 - PubMed
  23. N Engl J Med. 2005 Feb 3;352(5):476-87 - PubMed
  24. J Clin Oncol. 2000 Aug;18(16):2938-47 - PubMed

Publication Types